Kazazian Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Kazazian Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,071	Closed	-$208K	–	72
2018 Q4	$208K	Sell	5,071 -3,075	-38%	-$115K	0.28%	53
2018 Q3	$310K	Sell	8,146 -3,132	-28%	-$139K	0.29%	65
2018 Q2	$510K	Sell	11,278 -433	-4%	-$19.7K	0.47%	43
2018 Q1	$566K	Sell	11,711 -7,805	-40%	-$435K	0.59%	39
2017 Q4	$768K	Buy	19,516 +2,024	+12%	+$75.6K	0.78%	31
2017 Q3	$543K	Buy	+17,492	New	+$492K	0.66%	33

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Kazazian Asset Management's GBT Position: Q1 2019 in Review

Kazazian Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2019, closing a stake of 5,071 shares — an estimated $208K sold.

Kazazian Asset Management first reported a position in GBT in Q3 2017 and held it in 6 quarters. The position peaked at $768K in Q4 2017. 201 funds tracked by Wall St. Rank hold GBT as of Q1 2019.

Kazazian Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Kazazian Asset Management sold 5,071 Global Blood Therapeutics, Inc. shares in Q1 2019, an estimated $208K.
Kazazian Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2017 and held it in 6 quarters.
Kazazian Asset Management's Global Blood Therapeutics, Inc. position peaked at $768K in Q4 2017.
201 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.